Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445400
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-05-31
Brief Title:
A Study of BL-M07D1 BL-M07D1Pertuzumab and BL-M07D1PertuzumabDocetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sponsor:
Sichuan Baili Pharmaceutical Co Ltd
Organization:
Sichuan Baili Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-M07D1 BL-M07D1Pertuzumab and BL-M07D1PertuzumabDocetaxel as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a phase II clinical trial to evaluate the safety and efficacy of BL-M07D1 BL-M07D1Pertuzumab and BL-M07D1PertuzumabDocetaxel as first-line treatment in patients with unresectable locally advanced or metastatic HER2-positive breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None